For the last 30 years I have measured the plasma concentration of warfarin in man and animal and correlated it with the pharmacologic effect (O’Reilly, 1986). This effect of oral anticoagulants like warfarin is measured by the one-stage prothrombin time in plasma, which is easily quantitated. In the therapeutic monitoring of oral anticoagulants, the prothrombin time must be utilized and not the blood concentrations of the drug. Both the therapeutic efficacy and the clinical safety of these drugs in patients is achieved only by the careful control of the prothrombin time within narrow limits. The correlation of the plasma concentration of warfarin and the prothrombin-time response has yielded insights on the clinical use of racemic warfarin. For each of the entities described herein, the tables of data and the illustrations may be found in the original publications cited in the references.


Normal Human Subject Autosomal Dominant Transmission Metabolic Disposition Racemic Warfarin Warfarin Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Banfield, C., R. A. O’Reilly, E. Chan, and M. Rowland (1983). Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br. J. Clin. Pharmacol.,16, 669.PubMedCrossRefGoogle Scholar
  2. Link, K. P. (1943). Anticoagulant from spoiled sweet clover hay. Harvey Lect., 39, 162.Google Scholar
  3. Nagashima, R., R. A. O’Reilly, and G. Levy (1969). Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin. Pharmacol. Ther.,10, 22.PubMedGoogle Scholar
  4. O’Reilly, R. A. (1967). Studies on the coumarin anticoagulant drugs; interaction of human plasma albumin and warfarin sodium. J. Clin. Invest.,46, 329.Google Scholar
  5. O’Reilly, R. A. (1970). The second reported kindred of hereditary resistance to oral anticoagulant drugs. N. Engl. J. Med.,282, 1448.PubMedCrossRefGoogle Scholar
  6. O’Reilly, R. A. (1974). Drug interactions involving oral anticoagulants. Cardiovasc. Cl.,6, 23.Google Scholar
  7. O’Reilly, R. A. (1976). Vitamin K and the oral anticoagulant drugs. Annu. Rev. Med.,27, 245.PubMedCrossRefGoogle Scholar
  8. O’Reilly, R. A. (1986). Drug induced vitamin K deficiency, resistance, and drug interactions. In W. H. Seegers and D. A. Walz (Eds.), Prothrombin and Other Vitamin K Proteins, Vol. 11, CRC Press, Boca Raton, pp. 37–46.Google Scholar
  9. O’Reilly, R. A., and P. M. Aggeler (1968a). Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circulation, 38, 269.Google Scholar
  10. O’Reilly, R. A., and P. M. Aggeler (1968b). Phenylbutazone potentiation of anticoagulant effect: fluorometric assay of warfarin. Proc. Soc. Exp. Biol. Med., 128, 1080.Google Scholar
  11. O’Reilly, R. A., and P. M. Aggeler (1970). Determinants of the response to oral anticoagulant drugs in man. Pharmacol. Rev.,22, 35.PubMedGoogle Scholar
  12. O’Reilly, R. A., P. M. Aggeler, and L. S. Leong (1963). Studies on the coumarin anticoagulant drugs: pharmacodynamics of warfarin in man. J. Clin. Invest.,42, 1542.PubMedCrossRefGoogle Scholar
  13. O’Reilly, R. A., J. G. Pool, and P. M. Aggeler (1968). Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann. NY Acad. Sci., 151 913.PubMedGoogle Scholar
  14. O’Reilly, R. A., P. G. Welling, and J. G. Wagner (1971). Pharmacokinetics of warfarin following intravenous administration to man. Thromb. Diath. Haemorrh.,25, 178.PubMedGoogle Scholar
  15. O’Reilly, R. A., P. M. Aggeler, M. S. Hoag, and L. Leong (1962). Studies on the coumarin anticoagulant drugs; the assay of warfarin and its biologic application. Thromb. Diath. Haemorrh.,8, 82.Google Scholar
  16. O’Reilly, R. A., P. M. Aggeler, M. S. Hoag, L. S. Leong, and M. L. Kropatkin (1964). Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs:first reported kindred. N. Engl. J. Med.,271, 809.PubMedCrossRefGoogle Scholar
  17. O’Reilly, R. A., W. F. Trager, C. H. Motley, and W. Howald (1980). Stereoselective interaction of phenylbutazone with C12-/C13-warfarin pseudoracemates in man.J. Clin. Invest.,65, 746.PubMedCrossRefGoogle Scholar
  18. Pool, J. G., R. A. O’Reilly, L. J. Schneiderman, and M. Alexander (1968). Warfarin resistance in the rat. Am. J. Physiol., 215 627.PubMedGoogle Scholar
  19. Tucker, G. T., and M. S. Lennard (1990). Enantiomer specific pharmacokinetics. Pharmacol. Ther.,45, 309.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Robert A. O’Reilly
    • 1
    • 2
    • 3
  1. 1.Departments of MedicineSanta Clara Valley Medical CenterSan JoseUSA
  2. 2.The Stanford University Medical CenterStanfordUSA
  3. 3.The California Institute for Medical ResearchSan JoseUSA

Personalised recommendations